Payment overview · 2025
General Payments
$1,155.04
58 reported records · 18 companies
Healthcare provider profile · identity verified
Nisha Sharma, MD
Allopathic & Osteopathic Physicians|Family Medicine · IRVING, NY · NPI 1932103769
Verified facts
What the public records show
CMS Open Payments records show Nisha Sharma, MD received $1,155.04 in general payments during 2025 across 58 reported records.
Novo Nordisk Inc accounted for 19.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic, Paxlovid, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 166 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 226 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 363 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 307 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $223.52 | 19.4% | 13 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $164.17 | 14.2% | 8 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $145.01 | 12.6% | 8 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $100.60 | 8.7% | 6 | 2025 |
| Recor Medical Inc | Unresolved — no canonical attribution shown | $85.27 | 7.4% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $72.51 | 6.3% | 3 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $69.90 | 6.0% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $50.25 | 4.3% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $38.48 | 3.3% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $35.22 | 3.0% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $26.27 | 2.3% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $24.91 | 2.2% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.27 | 2.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $22.99 | 2.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.36 | 1.6% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $18.21 | 1.6% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $17.59 | 1.5% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $17.51 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,155.04 | 58 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $116.77 | 7 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $100.60 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $96.29 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $91.56 | 5 | 2025 |
Source payment records
|
|||||
| Paradise Ultrasound Renal Denervation System Normalized: paradise ultrasound renal denervation system |
Device | Recor Medical Inc | $85.27 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $82.12 | 5 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $72.51 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $67.88 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $56.94 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $51.49 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $50.25 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN Normalized: watchman |
Device | Boston Scientific Corporation | $47.72 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $35.22 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $32.82 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $26.27 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $24.91 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $24.27 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $22.99 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $22.61 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $22.18 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $21.24 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $20.10 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $18.38 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $18.36 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $18.21 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $17.59 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $17.59 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $17.51 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $16.84 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 307 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 226 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 91 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 363 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 18 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 114 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
166 | 40 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
114 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
226 | 65 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
91 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
128 | 30 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
363 | 64 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
307 | 75 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
18 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1126 | 297 |
| Amlodipine Besylate | Amlodipine Besylate | 1064 | 305 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1064 | 333 |
| Atorvastatin Calcium | Atorvastatin Calcium | 809 | 219 |
| Metoprolol Succinate | Metoprolol Succinate | 766 | 198 |
| Lisinopril | Lisinopril | 697 | 209 |
| Omeprazole | Omeprazole | 694 | 190 |
| Gabapentin | Gabapentin | 483 | 118 |
| Metformin Hcl Er | Metformin Hcl | 389 | 107 |
| Ozempic | Semaglutide | 363 | 64 |
| Furosemide | Furosemide | 352 | 109 |
| Losartan Potassium | Losartan Potassium | 345 | 102 |
| Hydrochlorothiazide | Hydrochlorothiazide | 334 | 89 |
| Pantoprazole Sodium | Pantoprazole Sodium | 332 | 92 |
| Eliquis | Apixaban | 307 | 75 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 291 | 108 |
| Metformin Hcl | Metformin Hcl | 286 | 85 |
| Famotidine | Famotidine | 267 | 86 |
| Trazodone Hcl | Trazodone Hcl | 251 | 74 |
| Alendronate Sodium | Alendronate Sodium | 248 | 71 |
| Simvastatin | Simvastatin | 246 | 68 |
| Ibuprofen | Ibuprofen | 245 | 75 |
| Metoprolol Tartrate | Metoprolol Tartrate | 240 | 63 |
| Tamsulosin Hcl | Tamsulosin Hcl | 234 | 68 |
| Jardiance | Empagliflozin | 226 | 65 |
| Sertraline Hcl | Sertraline Hcl | 220 | 63 |
| Irbesartan | Irbesartan | 207 | 61 |
| Fluticasone Propionate | Fluticasone Propionate | 200 | 77 |
| Duloxetine Hcl | Duloxetine Hcl | 195 | 57 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 189 | 51 |
| Escitalopram Oxalate | Escitalopram Oxalate | 170 | 42 |
| Potassium Chloride | Potassium Chloride | 166 | 46 |
| Synthroid | Levothyroxine Sodium | 166 | 40 |
| Azithromycin | Azithromycin | 155 | 109 |
| Atenolol | Atenolol | 149 | 43 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 143 | 37 |
| Pravastatin Sodium | Pravastatin Sodium | 136 | 39 |
| Baclofen | Baclofen | 130 | 36 |
| Alprazolam | Alprazolam | 129 | 48 |
| Trulicity | Dulaglutide | 128 | 30 |
| Citalopram Hbr | Citalopram Hydrobromide | 127 | 37 |
| Buspirone Hcl | Buspirone Hcl | 125 | 33 |
| Glimepiride | Glimepiride | 124 | 39 |
| Zolpidem Tartrate | Zolpidem Tartrate | 122 | 17 |
| Methylprednisolone | Methylprednisolone | 121 | 94 |
| Montelukast Sodium | Montelukast Sodium | 121 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 117 | 37 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 114 | 22 |
| Amitriptyline Hcl | Amitriptyline Hcl | 113 | 26 |
| Carvedilol | Carvedilol | 109 | 28 |
| Lovastatin | Lovastatin | 107 | 27 |
| Meloxicam | Meloxicam | 103 | 29 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 101 | 21 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 91 | 27 |
| Mounjaro | Tirzepatide | 91 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 87 | 21 |
| Spironolactone | Spironolactone | 87 | 24 |
| Allopurinol | Allopurinol | 86 | 25 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 84 | 18 |
| Ezetimibe | Ezetimibe | 84 | 33 |
| Bupropion Hcl Sr | Bupropion Hcl | 83 | 22 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 78 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 75 | 21 |
| Celecoxib | Celecoxib | 72 | 15 |
| Ondansetron Odt | Ondansetron | 71 | 19 |
| Prednisone | Prednisone | 69 | 32 |
| Valsartan | Valsartan | 69 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 68 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 67 | 24 |
| Paroxetine Hcl | Paroxetine Hcl | 67 | 21 |
| Warfarin Sodium | Warfarin Sodium | 66 | 17 |
| Glipizide | Glipizide | 64 | 21 |
| Valacyclovir | Valacyclovir Hcl | 64 | 30 |
| Pioglitazone Hcl | Pioglitazone Hcl | 63 | 19 |
| Bupropion Xl | Bupropion Hcl | 62 | 18 |
| Clonidine Hcl | Clonidine Hcl | 61 | 12 |
| Amoxicillin | Amoxicillin | 59 | 39 |
| Hydralazine Hcl | Hydralazine Hcl | 59 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 59 | 38 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 56 | 17 |
| Glipizide Er | Glipizide | 56 | 16 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 55 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 54 | 16 |
| Enalapril Maleate | Enalapril Maleate | 53 | 14 |
| Xarelto | Rivaroxaban | 53 | 17 |
| Vascepa | Icosapent Ethyl | 52 | suppressed |
| Topiramate | Topiramate | 51 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 50 | 14 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 49 | 12 |
| Fenofibrate | Fenofibrate,micronized | 48 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 48 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 48 | 11 |
| Azelastine Hcl | Azelastine Hcl | 47 | 19 |
| Doxycycline Hyclate | Doxycycline Hyclate | 47 | 42 |
| Icosapent Ethyl | Icosapent Ethyl | 47 | 15 |
| Bumetanide | Bumetanide | 46 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 46 | 14 |
| Meclizine Hcl | Meclizine Hcl | 46 | 15 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 46 | 14 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 45 | suppressed |
| Fenofibrate | Fenofibrate | 45 | 14 |
| Myrbetriq | Mirabegron | 45 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 44 | 14 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 44 | suppressed |
| Mirtazapine | Mirtazapine | 44 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 44 | 23 |
| Dutasteride | Dutasteride | 43 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 43 | 17 |
| Ondansetron Hcl | Ondansetron Hcl | 43 | 19 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 43 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 42 | 32 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 42 | 32 |
| Pregabalin | Pregabalin | 42 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 42 | suppressed |
| Telmisartan | Telmisartan | 41 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 41 | 14 |
| Colchicine | Colchicine | 40 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 39 | suppressed |
| Lansoprazole | Lansoprazole | 38 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 38 | suppressed |
| Aripiprazole | Aripiprazole | 37 | suppressed |
| Entresto | Sacubitril/Valsartan | 36 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 36 | 21 |
| Cholestyramine | Cholestyramine (With Sugar) | 35 | 19 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 35 | 29 |
| Mupirocin | Mupirocin | 35 | 21 |
| Tramadol Hcl | Tramadol Hcl | 35 | 20 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 34 | 30 |
| Cephalexin | Cephalexin | 34 | 25 |
| Memantine Hcl | Memantine Hcl | 34 | 11 |
| Finasteride | Finasteride | 33 | suppressed |
| Levetiracetam | Levetiracetam | 33 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 33 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 31 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 31 | suppressed |
| Primidone | Primidone | 31 | suppressed |
| Carbamazepine Er | Carbamazepine | 30 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 30 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 29 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 29 | 12 |
| Benzonatate | Benzonatate | 28 | suppressed |
| Lorazepam | Lorazepam | 28 | suppressed |
| Linzess | Linaclotide | 27 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 27 | suppressed |
| Diazepam | Diazepam | 26 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 25 | 20 |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 24 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 24 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 24 | suppressed |
| Verapamil Er | Verapamil Hcl | 24 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Estradiol | Estradiol | 23 | 11 |
| Fluconazole | Fluconazole | 22 | 16 |
| Droplet Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Methocarbamol | Methocarbamol | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Acyclovir | Acyclovir | 20 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 20 | suppressed |
| Loperamide | Loperamide Hcl | 20 | suppressed |
| Methimazole | Methimazole | 20 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 20 | 15 |
| Propranolol Hcl Er | Propranolol Hcl | 20 | suppressed |
| Risperidone | Risperidone | 20 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Tadalafil | Tadalafil | 18 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 17 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 17 | suppressed |
| Clonazepam | Clonazepam | 16 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 16 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 15 | suppressed |
| Cefdinir | Cefdinir | 15 | 13 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 15 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 15 | suppressed |
| Repatha Sureclick | Evolocumab | 15 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Invokana | Canagliflozin | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Nyamyc | Nystatin | 14 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 13 | suppressed |
| Calcium Acetate | Calcium Acetate | 13 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 13 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 12 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Ibu | Ibuprofen | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Modafinil | Modafinil | 12 | suppressed |
| Nystop | Nystatin | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 12 | suppressed |
| Zafirlukast | Zafirlukast | 12 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 11 | suppressed |
| Ciclopirox | Ciclopirox | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Ssd | Silver Sulfadiazine | 11 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,155.04 · 58 records | Novo Nordisk Inc | AIRSUPRA, Auvelity, CAPLYTA, CAPVAXIVE, Cologuard Collection Kit, ELIQUIS, FREESTYLE LIBRE 3, GARDASIL 9, GEMTESA, JARDIANCE, Korlym, MOUNJARO, NURTEC ODT, OTEZLA, Omnipod, Ozempic, PAXLOVID, Paradise Ultrasound Renal Denervation System, REPATHA, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, WATCHMAN, WATCHMAN FLX, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error